MIMaike Ihnen

Maike Ihnen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maike Ihnen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients

    by Maike Ihnen, Kerstin Kress, Jan Felix Kersten, Ergin Kilic, Matthias Choschzick, Hilke Zander, Volkmar Müller, Sven Mahner, Fritz Jänicke, Linn Woelber, et al.

    Background: An altered expression of the activated leukocyte cell adhesion molecule (ALCAM) is associated with cancer progression in various cancer types. In some cancers ALCAM has a prognostic value or is predictive for the benefit of therapeutic interventions. To date there are no data on the role of ALCAM in cervical cancer available. Methods: In this study, ALCAM expression was analysed by immunohistochemistry (IHC) in tissue samples of 233 patients with cervical cancer, among them 178 with complete follow-up information. In addition, soluble (s-)ALCAM was measured in sera of a subset of the included patients (n = 55) by enzyme-linked immunosorbent assay (ELISA). Results: ALCAM overexpression was detected (immunoreactive score (IRS) 2-12) in 58.4% of the cervical cancer samples. The normal ectocervical or endocervical epithelium showed no ALCAM reactivity. In untreated patients, ALCAM overexpression in tumor tissue tended to be associated with shorter cancer-specific survival (CSS) and disease-free survival (DFS). Patients, whose tumor samples showed ALCAM overexpression receiving a cytotoxic therapy like radiotherapy or chemoradiation, however, had a favourable prognosis compared to those patients, whose cancers showed no or minimal ALCAM staining. This effect was particularly apparent in patients receiving chemoradiation where the CSS was significantly longer in patients with ALCAM-positive tumors (p = 0.038; cumulative incidence rates at 96 months 8%, 95% CI 0%-23%, and 26%, CI 3%-43% in ALCAM-positive and ALCAM-negative cases, respectively). Median preoperative s-ALCAM concentration in sera from tumor patients was 27.6 ng/ml (range 17.5-55.1 ng/ml, mean 28.9 ng/ml), serum levels did not correlate with intratumoral ALCAM expression. Conclusions: The data of our retrospective study suggest that the prognostic value of ALCAM expression in cervical carcinoma might be therapy-dependent, and that ALCAM might function as a predictive marker for the response to chemoradiation. This should be confirmed in further, prospective studies.


  • Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin

    by Maike Ihnen, Ergin Kilic, Nadine Köhler, Thomas Löning, Isabell Witzel, Christian Hagel, Sylvia Höller, Jan F Kersten, Volkmar Müller, Fritz Jänicke, et al.

    Aims For prediction and understanding of underlying mechanisms of organ-specific metastases, various gene and protein expression signatures have been identified in primary breast carcinomas. These expression signatures often include several genes coding for adhesion molecules, such as activated leucocyte cell adhesion molecule (ALCAM/CD166) and carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), both of which may play an important role in the development of distant metastases because of their adherent properties. Owing to their predominantly membranous localisation, they are also considered to have certain therapeutic potential. Apart from expression data obtained in the primary tumour, data for gene and protein expression patterns in distant breast cancer metastases are rare. Therefore this study focuses on analysing the distribution of ALCAM and CEACAM6 protein expression in breast cancer metastases from different sites. Methods Immunohistochemical staining for ALCAM and CEACAM6 in 117 breast cancer metastases derived from liver (n=24), lung (n=19), brain (n=21), bone (n=36) and skin (n=17) was performed. Results Immunoreactive scores (IRS) for ALCAM in all metastases except skin metastases ranged from 2.63 to 5.10 (membranous) and 2.79 to 3.67 (cytoplasmic), showing a positive correlation with each other (r=0.690, pConclusions Compared with CEACAM6, ALCAM showed significantly stronger protein expression in breast cancer skin metastases compared with metastases in all other sites.


  • Open Access

    Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer

    by Linn Woelber, Kerstin Kress, Jan F Kersten, Matthias Choschzick, Ergin Kilic, Uwe Herwig, Christoph Lindner, Joerg Schwarz, Fritz Jaenicke, Sven Mahner, et al.

    Carbonic anhydrase IX (CAIX) is a membranous expressed metalloenzyme involved in pH homeostasis and cell adhesion. The protein is overexpressed in a variety of tumors and potentially associated with negative outcome. This study was designed to investigate the prognostic role of CAIX in serum and tumor tissue of patients with primary cervical cancer. Tumor samples of 221 consecutive patients with primary cervical cancer who underwent surgery between 1993 and 2008 were analyzed for CAIX expression by immunohistochemistry. Additionally, preoperative serum CAIX concentrations were determined by ELISA in a subset of patients. Correlation with intratumoral CAIX expression as well as clinicopathological factors and outcome was analyzed. CAIX expression was observed in 81.9% of the tumor specimens; 62.0% showed a moderate or strong staining intensity. Moderate/strong expression was associated with squamous histology (p = 0.024), advanced tumor stage (p = 0.001), greater invasion depth (p = 0.025), undifferentiated tumor grade (p < 0.001) and high preoperative SCC-Ag values (p = 0.042). Furthermore patients with moderate/strong intratumoral CAIX expression had a higher number of metastatic lymph nodes compared to those with none/weak intratumoral expression levels (p = 0.047) and there was a non-significant association between high intratumoral CAIX expression and shorter survival (p = 0.118). Preoperative serum concentrations of CAIX ranged between 23 and 499 pg/mL and did not correlate with intratumoral expression or other clinicopathological variables. CAIX is associated with advanced tumor stages and lymph node metastases in cervical cancer, potentially representing a new target in this disease. In contrast to other epithelial cancers we could not observe a correlation between serum CAIX and its intratumoral expression.


  • Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer

    by M. Ihnen, V. Müller, R. M. Wirtz, C. Schröder, S. Krenkel, I. Witzel, B. W. Lisboa, F. Jänicke, K. Milde-Langosch

    Activated Leukocyte Cell Adhesion Molecule (ALCAM, also called CD 166, MEMD) as cell surface immunoglobulin is reported as prognostic marker in breast cancer, but its predictive value has not yet been evaluated. We have analyzed ALCAM protein expression by Western Blot analysis (n = 160) and mRNA expression by cDNA microarray analysis (n = 162) in primary mammary carcinomas. Both expression results were obtained in 133 cases, showing a strong positive correlation between protein expression and mRNA expression (P < 0.001). Neither ALCAM protein nor mRNA expression are correlated to histological type, grading, stage or age of patient. However, ALCAM protein expression correlates positively with estrogen receptor status (ER) (P = 0.025). A stratified subgroup analysis showed positive correlation of high ALCAM mRNA expression with longer overall survival (OAS; P = 0.0012) in patients treated with adjuvant chemotherapy (n = 100). In contrast, patients with high ALCAM mRNA expression who did not receive chemotherapy tended to have a worse prognosis. Similar but weaker correlations were found regarding ALCAM protein expression data. The predictive impact of ALCAM mRNA expression in chemotherapy treated patients was corroborated by multivariate Cox regression analysis also including histopathological markers (P = 0.001 for OAS). Our overall results reveal that high ALCAM expression levels in primary tumors might be a suitable marker for prediction of the response to adjuvant chemotherapy in breast cancer.


  • Behandlungsstrategien von Condylomata acuminata in der Schwangerschaft: Fallbericht und Literaturstudie

    by M. Ihnen, S. Mahner, J. Schwarz

    Wir berichten von einer 24-jährigen Erstgravida, mit ausgedehnten Condylomata acuminata in der 13. SSW. Neben der ästhetischen Komponente und der zum Teil erheblichen Beschwerdesymptomatik, wird die Infektion des Neugeborenen sub partu wegen einer HPV-assoziierten Papillomatose gefürchtet. Generelle Therapieoptionen bei Condylomatose sind die immunmodulatorische Behandlung mit Imiquimod oder die lokale Anwendung von Podophyllin, 5-Fluoruracil und Trichloressigsäure sowie die Kryo- oder Lasertherapie. Als weitere Therapieoptionen stehen die chirurgische Exzision und die Applikation von Interferon alpha oder gamma lokal oder auch systemisch zur Verfügung. Die Laservaporisation wird zur Behandlung einer Kondylomatose in der Schwangerschaft als effektivste und komplikationsarme Behandlungsmethode herausgestellt. Andere Therapieoptionen insbesondere Imiquimod, Interferon und 5-Fluoruracil gelten in der Schwangerschaft als weitgehend kontraindiziert. Neben den etablierten Therapeutika werden immunstimulierende Phytotherapeutika eingesetzt, z.B. der Familie der Thuja (Cupressaceae, Lebensbaum). Um vorerst eine Laservaporisation der Vulva und Vagina in Narkose zu umgehen, wurde die o.g. Patientin zunächst systemisch mit 3×20 Tropfen Thuja-Mischrezeptur (Thuja-Oligoplex®, Madaus) behandelt. Die in der 30. SSW durchgeführte Kontrolluntersuchung zeigte eine fast vollständige Remission. Im Verlauf waren keine weiteren Kondylome mehr nachweisbar. Die hier vorgestellte Kasuistik zeigt, dass auch eine ausgedehnte Kondylomatose in der Schwangerschaft mit nebenwirkungsarmen Medikamenten oder spontan komplett rückläufig sein kann. Unser Therapieregime besteht daher zunächst in regelmäßigen Kontrollen, sowie gegebenenfalls einer immunstimulierenden Therapie. Besteht weiterhin eine ausgedehnte Kondylomatose und wünscht die Patientin eine vaginale Entbindung, so führen wir eine Laservaporisation erst zwischen der 34. und 36. Schwangerschaftswoche durch.

  • Regression von Condylomata acuminata in der Schwangerschaft nach systemischer Therapie mit Thuja

    by M. Ihnen, S. Mahner, J. Schwarz

    Wir berichten von einer 24-jährigen Erstgravida, bei der erstmals bei zuvor unauffälliger gynäkologischer Untersuchung in der 13. SSW im Bereich des Hymenalsaums, perianal sowie vaginal, multiple Kondylome diagnostiziert wurden. Die Patientin wurde daraufhin systemisch mit 3 × 20 Tropfen Thuja-Mischrezeptur (Thuja-Oligoplex®, Madaus) behandelt. Auf andere therapeutische Maßnahmen wurde verzichtet. Die in der 30. SSW durchgeführte Kontrolluntersuchung zeigte eine fast vollständige Remission der vordiagnostizierten Kondylome, lediglich im Bereich des Hymenalsaumes konnten noch stecknadelkopfgroße Kondylome nachgewiesen werden. Die Patientin wurde in der 39. Schwangerschaftswoche von einem gesunden, 3300 g schweren Mädchen vaginal entbunden. Im Verlauf waren keine weiteren Kondylome mehr nachweisbar. A twenty-five year old female patient presented with anogenital warts at 13 weeks' gestation at our outpatient clinic. Clinical examination confirmed extensive soft, fleshy condylomata acuminata in the hymenal area, the vagina and the perianal region. She was treated systemically with a Thuja-mixture (Thuja-Oligoplex®, Madaus, Germany), no surgical treatment or laser therapy was performed. At 30 weeks' gestation clinical examination revealed an almost complete remission. There were only a few warts left in the hymenal area. No relapse was reported until her uncomplicated vaginal delivery in week 39. Her female child had a weight of 3300 g and the Apgar score was normal. All further clinical examinations gave no sign of recrudescence.